AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation

The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of non –small cell lung cancer (NSCLC) patients, with higher objective response rates and increased progression-free survival compared to former cytotoxic chemotherapy [1–3]. However, durable responses cannot be achieved as acquired resistance to EGFR TKIs inevitably develops [4]. Therefore, investigat ion into the molecular mechanisms of acquired resistance and subsequent development of novel drugs to overcome such resistance are essential in the treatment of NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cabozantinib;   Drug: Atezolizumab;   Drug: Docetaxel Sponsors:   Hoffmann-La Roche;   Exelixis;   Chugai Pharmaceutical Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Conclusion: Our results suggest that conventional platinum-based chemotherapy negatively impacts the immune microenvironment at the time point of secondary progression.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations. Dete...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Our case reports an advanced EGFR ‐mutant lung adenocarcinoma patient achieved PR and a PFS of 6 months to a combination of immunotherapy and anti‐angiogenic agent, sintilimab and bevacizumab, as subsequent‐line therapy. Sintilimab and bevacizumab combination therapy was well‐tolerated and effective, resulting in dramatic tu mor reduction and improvement in clinical symptoms. A 53 ‐year‐old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first‐line setting. After disease progression, he received targeted therapy because of subsequent detection ofEG...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Conclusion: These results suggested improved outcomes with entrectinib versus crizotinib/chemotherapy and may help to make better informed treatment decisions. PMID: 32648475 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
Lung cancer is the second most common cancer in the United States with a 5-year relative survival rate of only 18 % [1]. A widely used non-small cell lung cancer (NSCLC) chemotherapy treatment is gemcitabine in combination with carboplatin which is also used in the treatment of other solid tumors such as bladder, ovarian and breast cancer. Gemcitabine/carboplatin treatment is known to cause severe toxicity that can lead to the need for postponed treatment, reduced doses and in some cases even discontinuation of treatment [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Madam — Recent Royal College of Radiologists' treatment guidelines for lung cancer during the COVID-19 pandemic [1] motivated us to share the findings of our recent audit of accelerated hypofractionated concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC; SOCCAR regime n): 55 Gy in 20 fractions over 26 days with concomitant chemotherapy (cisplatin and vinorelbine) [2].
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
This study aims to compare the efficacy of ICIs with conventional therapy in NSCLC patients with bone, brain or liver metastases.Materials and Methods: MEDLINE, Embase, and CENTRAL were searched for studies comparing ICIs with conventional therapy in NSCLC patients with bone, brain or liver metastases. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) among included studies was analyzed using the random effects model.Results: Eight studies consisting of 988 NSCLC patients were included, 259 with brain metastases and 729 with liver metastases. No available study with bone metastases i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionUp to 8.0  mg/m2/days YM155 administered every 3  weeks in combination with erlotinib exhibited a favorable safety profile and moderate clinical efficacy. These results suggest that inhibiting survivin is a potential therapeutic strategy for select patients with EGFR TKI refractory NSCLC.Trial registrationUMIN000031912 at UMIN Clinical Trials Registry (UMIN-CTR).
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer